Functional approach coupled with proteomic analysis permitted to identify F11R/JAM-A as a promising cancer drug target [20] in conjunction with observations that F11R/JAM-A can serve as a cell surface marker for high-throughput flow cytometry-based characterization of TNBC cancer stem cells (CSCs) [21]. This evidence concerns the gene F11R and cancer.